Investing.comCodex · 实盘不做把握 6/10
北京时间·🕒 发布 21:27:48时区推断·⟳ 抓取 21:29:46·⚡ 决策 07-23 21:33:41 +3m55s·96.0 天前
安捷伦PD-L1 IHC 22C3 pharmDx卵巢癌伴随诊断获欧盟认证
欧盟认证扩大PD-L1 IHC 22C3 pharmDx在卵巢癌中的适用范围，为KEYTRUDA治疗筛选患者。
📄 原文Investing.com↗ 原文
Agilent stock rises on EU approval for cancer diagnostic
Oil prices top $100 a barrel after Houthis attack Saudi tankers in Red Sea Investing.com -- Agilent Technologies Inc. (…
不做 安捷伦（A.US）
欧盟认证是正面但金额未披露，且美国FDA同类批准已在2月发生；对安捷伦体量不足以构成短线ENTER。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 安捷伦此前已获美国FDA批准PD-L1 IHC 22C3 pharmDx用于卵巢癌KEYTRUDA伴随诊断。
- Labcorp宣布在美国推出该FDA批准伴随诊断，说明商业化路径已有区域先例。
- 媒体称安捷伦获欧盟认证，盘前一度上涨3.2%。市场反应:A.US最新报价133.46美元，较前收0%。
关键理由
- 欧盟认证扩大PD-L1 IHC 22C3 pharmDx在卵巢癌中的适用范围，为KEYTRUDA治疗筛选患者。
- 安捷伦2025财年收入69.5亿美元，单个伴随诊断新增适应症未披露销售额或利润分成，难以形成相对公司体量的短线重定价。
- 同类美国FDA适应症扩展已在2026年2月获批并由Labcorp于4月商业推广，欧盟认证更像区域扩展而非全新产品。
主要风险
- 未披露可量化新增检测量、单价或收入贡献。
- A.US报价133.46美元、当日0%，市场未显示强烈重定价。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-02-11 · 影响 weakens
同一疾病适应症的美国批准和商业发布已较早发生，欧盟认证增量有限。
检索:Agilent PD-L1 IHC 22C3 ovarian cancer FDA approval February 2026 Labcorp launch April 2026 原文 ↗
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- normalize_ticker · 结果未知
原文全文
展开原文 · 1,935 字
Oil prices top $100 a barrel after Houthis attack Saudi tankers in Red Sea
Investing.com -- Agilent Technologies Inc. (NYSE:A) shares rose 3.2% in premarket trading Thursday following the company’s announcement that it received European Union certification for its PD-L1 IHC 22C3 pharmDx companion diagnostic for ovarian cancer.
The approval allows the diagnostic to be used to identify patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 and may be eligible for treatment with Merck’s KEYTRUDA (pembrolizumab).
The diagnostic enables pathologists to assess PD-L1 expression to support treatment decisions in a disease where therapeutic options remain limited for many patients. This marks the eighth CE-marked companion diagnostic indication currently available for PD-L1 IHC 22C3 pharmDx, Code SK006, in the EU.
PD-L1 expression in epithelial ovarian, fallopian tube, or primary peritoneal carcinoma was evaluated using the diagnostic in the KEYNOTE-B96/ENGOT-ov65 clinical trial, supporting its use in identifying patients who may be eligible for treatment with pembrolizumab in the platinum-resistant setting.
The diagnostic is also indicated in the EU to help physicians identify patients across several other tumor types, including non-small cell lung cancer, esophageal cancer, cervical cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, gastric or gastroesophageal junction adenocarcinoma, and urothelial carcinoma, who may be eligible for treatment with KEYTRUDA.
Agilent developed PD-L1 IHC 22C3 pharmDx, Code SK006, in partnership with Merck as a companion diagnostic for KEYTRUDA. The Santa Clara, California-based company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Investing.com -- Agilent Technologies Inc. (NYSE:A) shares rose 3.2% in premarket trading Thursday following the company’s announcement that it received European Union certification for its PD-L1 IHC 22C3 pharmDx companion diagnostic for ovarian cancer.
The approval allows the diagnostic to be used to identify patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 and may be eligible for treatment with Merck’s KEYTRUDA (pembrolizumab).
The diagnostic enables pathologists to assess PD-L1 expression to support treatment decisions in a disease where therapeutic options remain limited for many patients. This marks the eighth CE-marked companion diagnostic indication currently available for PD-L1 IHC 22C3 pharmDx, Code SK006, in the EU.
PD-L1 expression in epithelial ovarian, fallopian tube, or primary peritoneal carcinoma was evaluated using the diagnostic in the KEYNOTE-B96/ENGOT-ov65 clinical trial, supporting its use in identifying patients who may be eligible for treatment with pembrolizumab in the platinum-resistant setting.
The diagnostic is also indicated in the EU to help physicians identify patients across several other tumor types, including non-small cell lung cancer, esophageal cancer, cervical cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, gastric or gastroesophageal junction adenocarcinoma, and urothelial carcinoma, who may be eligible for treatment with KEYTRUDA.
Agilent developed PD-L1 IHC 22C3 pharmDx, Code SK006, in partnership with Merck as a companion diagnostic for KEYTRUDA. The Santa Clara, California-based company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。